Refine by
Research In Oncology Articles & Analysis: Older
384 news found
“This collaboration with Weill Cornell Medicine contributes to our ongoing development initiatives in breast cancer research.," states Dr. Holger Neecke, CEO of Tethis. "Our See.d instrument prepares high-quality samples, ensuring precise measurement of both cellular and cell-free tumor markers in blood. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its ...
It primarily serves researchers with its state-of-the-art facilities and experienced team, which specializes in the synthesis and development of a broad range of drug conjugates. ...
In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was recently presented at the ESMO ...
Additionally, through a dedicated real-world evidence study, researchers will be able to evaluate the operational benefits of liquid biopsy testing, including the speed of results and the ability of users to consistently achieve high-quality data in a variety of laboratory settings. ...
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). ...
CD Genomics, a pioneering leader in genomic solutions, is proud to announce its cutting-edge whole genome sequencing (WGS) services. Utilizing the latest technologies from Illumina and PacBio platforms, CD Genomics offers precise and affordable sequencing solutions for a wide range of organisms, including viruses, microbes, plants, animals, and humans. Whole genome sequencing represents a ...
Amerigo Scientific, a distributor focused on providing critical products and services to biomedical and life science communities, aims to enhance cell culture results by providing researchers and laboratories with a variety of simple and high-performance 3D cell culture systems. Three-dimensional (3D) cell culture provides an artificially created microenvironment to achieve optimal cell growth, ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. Studies found that the incidence rate of PC has been ...
The International Agency for Research on Cancer reports that as recently as 2020, there were over 13,000 new cases of cancer in Puerto Rico. Tragically, there were also more than 5,500 deaths due to cancer in Puerto Rico that year alone. The American Association for Cancer Research has reported that more than 40% of all diagnosed cancers in the U.S. can be attributed to preventable causes. ...
The U.S. Department of Energy announced this week (Jan 24) that it will play a key role in the National Artificial Intelligence Research Resource (NAIRR) pilot as part of President Biden's push to ensure the United States is a leader in harnessing the promise and managing the risks of artificial intelligence (AI). This pilot, led by the U.S. National Science Foundation (NSF), aims to develop a ...
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...
CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on ...
ByCELLINK
CD Genomics, a prominent leader in the next generation sequencing arena, proudly announce the launch of a groundbreaking 5mC/5hmC sequencing service. This innovative service is poised to empower researchers by providing a deeper insight into epigenetic variations, unlocking the mysteries of epigenetics, and catalyzing pivotal advancements in the realm of life science research and precision ...
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
ByCELLINK
“We are looking forward to seeing the impact of this partnership on the oncology research community and look forward to the advancements that will be made in cancer research through the use of Carcinotech’s optimized cancer models. ...
ByCELLINK
CD Genomics, a trailblazing genomics and bioinformatics services provider, is delighted to announce the launch of the Long Amplicon Analysis (LAA) service, a mature genomic research method that promises to revolutionize the field. With LAA, scientists can now explore intricate genomic landscapes, facilitating groundbreaking discoveries and advancements in various branches of genomics. Long ...
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. Real world evidence is important to understand what is happening to patients in healthcare2, so AngioDynamics welcomed the news last week that the UK’s National Institute ...
CD Genomics, a global leader in transcriptomics solutions, unveils its mature Nanopore Direct RNA Sequencing service that can propel transcriptomics research to new heights. With this service, CD Genomics empowers researchers to unlock the full potential of their studies with unrivalled precision and efficiency. Harnessing the power of Oxford Nanopore sequencing technology, this revolutionary ...
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer ...
ByBayer AG